抗血管内皮生长因子类药物在新生血管性青光眼及滤过手术抗瘢痕治疗中的应用  

Application of anti-VEGF agents in treatment of neovascular glaucoma and anti-scarring in filtering surgery

作　　者：贾旭[1] 段宣初[1] 

机构地区：[1]中南大学湘雅二医院眼科,长沙410011

出　　处：《中华眼科杂志》2015年第4期314-318,共5页Chinese Journal of Ophthalmology

摘　　要：新生血管性青光眼（NVG）是一种由多种疾病导致视网膜缺血缺氧而发生的继发性青光眼,研究发现其病因与VEGF有关。目前,抗VEGF药物作为治疗NVG的手段之一,已成为现阶段青光眼研究领域的热点,为提高NVG疗效开辟了新的途径。本文就有关NVG病理生理基础与临床过程,包括Bevacizumab、Ranibizumab、Pegaptanib及Aflibercept在内的4种抗VEGF药物的基础研究,抗VEGF药物在NVG及滤过手术抗瘢痕治疗中应用的国内外研究进展进行综述,以期为临床治疗NVG、提高手术成功率提供参考。Neovascular glaucoma （NVG） is a group of secondary glaucoma which led by a variety of diseases that have anoxia or ischemia to the retina.Some studies have found that the etiology was related to the vascular endothelial growth factor（VEGF）.At present,anti-VEGF as a treatment method to NVG,has become an important advancc in the field of glaucoma research,which established a new way to improve the prognosis.This review mainly focused on the pathophysiologic basis and clinical research of NVG,fundamental research and applications about four kinds of anti-VEGF agents （Bevacizumab,Ranibizumab,Pegaptanib and Aflibercept） and application of treatment of NVG and anti-scarring in filtering surgery.The review also provided references for the clinical treatment of NVG and improving the success rate of operation.

关 键 词：青光眼 新生血管性 滤过外科手术 血管生成抑制剂 抗体 单克隆 人 

分 类 号：R779.6[医药卫生—眼科]